Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Liked2Thinkon Oct 14, 2022 1:02pm
135 Views
Post# 35025133

RE:RE:RE:Grail even less accurate than previously thought

RE:RE:RE:Grail even less accurate than previously thought
LithLover wrote: Glad you asked Here are the published results:


Grail in Annals of Oncology:

https://www.annalsofoncology.org/article/S0923-7534(21)02046-9/fulltext

Overall sensitivity for cancer signal detection was 51.5% (49.6% to 53.3%); sensitivity increased with stage [stage I: 16.8% (14.5% to 19.5%), stage II: 40.4% (36.8% to 44.1%), stage III: 77.0% (73.4% to 80.3%), stage IV: 90.1% (87.5% to 92.2%)]. Stage I-III sensitivity was 67.6% (64.4% to 70.6%) in 12 pre-specified cancers that account for approximately two-thirds of annual USA cancer deaths and was 40.7% (38.7% to 42.9%) in all cancers.


Aristotle in Journal of Clinical Oncology

https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e15037

Aristotle classified cancer profiles with sensitivities from 55.6-100% and positive predictive values from 5.6-77.7% at a specificity of 99.0% (Table). 



 
Liked2Think wrote:
LithLover wrote: Grail test found to have even more false positives than before. Imagine taking the test being told you have cancer and than finding out the test was only 38% accurate.  

29.8% of the participants with false alarms underwent invasive procedures

Sept 12, 2022

https://www.medtechdive.com/news/amid-merger-turmoil-illuminas-grail-unit-reports-downturn-in-accuracy-of/631583/

  • Updated data on Grail’s multi-cancer early detection blood test Galleri suggest the diagnostic is less accurate than previously thought. 
  • Last year, Grail reported that 44.6% of patients with positive test results actually had cancer. In the latest analysis, the figure, known as the positive predictive value, has fallen to 38.0%.
  • News of the falling predictive power seen in the study, which used an old version of Galleri, comes amid growing doubts about the fate of the Illumina-Grail merger, which the European Commission has blocked.

 


Has there ever been any 3rd party verification that the Aristotle test is any better or is that just another thing investors should just believe from a ceo that hasn't been able to keep his word multiple times in the past?
 




How many of Stage's patients that have been diagnoised with cancer through aristotle actually had cancer?  Is there any real world data at all?

Aristotle classified cancer profiles with sensitivities from 55.6-100%

What were the numbers betwen the two vastly different percentages?  Is a 55.6% great?  Yes better than 38% and maybe the numbers overall were closer to 100% but whats the actual numbers?

No one in this space seems to have the ability to track the simpliest of things.

<< Previous
Bullboard Posts
Next >>